All Oncology News

While hospitals and cancer centers are taking cues from the hospitality industry, office practices are learning that improving the patient flow aids in running an efficient office.

While hospitals and cancer centers are taking cues from the hospitality industry-think hoteliers like Marriott, Hyatt, and even Ritz-Carlton-office practices are learning that improving the patient flow aids in running an efficient office. That is translating into increased profitability.

A new medication tracking system to counter drug diversion and counterfeiting might have some oncologists feeling a little safer about the chemotherapy they prescribe for their patients.

OncLive brings total of 29 esteemed oncologists to awards panel for insight.

Dartmouth University researchers started investigating the phenomenon called the Cherenkov effect in 2011

OncLive will work with Georgia's only NCI-designated cancer center to support its efforts to conduct innovative, multidisciplinary research and translate that knowledge into excellent patient care.

When a patient receives the diagnosis of cancer, regardless of stage or severity of the disease, one of the many questions asked is how to pay for the treatment.

Last Wednesday, the House of Representatives voted on the Consolidated Appropriations Act of 2014, with the Senate passing the bill last night.

The Office of the National Coordinator for Health Information Technology has released a set of guides and interactive tools to help medical practices improve their use of electronic health records.

Researchers in the Department of Radiation Oncology at the University of North Carolina Hospitals found that almost one-third of low-risk and almost one-half of intermediate-risk prostate cancer patients received a staging bone scan.

A new report about healthcare provider experience with clinical decision support tools says the systems are not integrated enough to deliver the strategic direction providers are looking for.

The Centers for Medicare & Medicaid Services will make public a once previously confidential database of Medicare claims.

The BRAF inhibitor dabrafenib (Tafinlar) has received a Breakthrough Therapy designation from the FDA for its potential as a treatment for patients with metastatic BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) who have received at least one prior line of platinum-containing chemotherapy.

A survey of 46 representatives from accountable care organizations (ACOs) indicates that critical gaps remain in the organizations' ability to support, manage, and ensure appropriate medication use.

Patient care is shifting from inpatient to outpatient settings, especially in oncology.

The FDA has granted an accelerated approval to the combination of the MEK inhibitor trametinib and the BRAF inhibitor dabrafenib as a treatment for patients with unresectable or metastatic melanoma that harbors a BRAF V600E or V600K mutation.

With the October deadline for ICD-10 transition looming, now might be the time to consider integrating current electronic health records systems with clinically-driven revenue cycle management (RCM) software.

The transition to ICD-10 is likely to cost your practice both time and money, making a smooth implementation process all the more important.

On December 30th, the United States Preventive Services Task Force (USPSTF) announced they recommend annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 55-80 years who have a 30 pack-year smoking history.

Provider-based research networks (PBRNs) make clinical trials available to community-based practices.

Although the changeover to using ICD-10 billing codes won't be mandatory until October 1, 2014, there are many coding changes to consider starting on January 1. Specifically, the reimbursement rate for some genetic testing and imaging involving breast cancer will see significant changes.

As new cancer therapies have prolonged life, an interesting question has arisen among community oncologists: "Is it better to transfer long-term cancer survivors to general practitioners or develop clinics for long-term survivors within cancer centers?"

A novel imaging technology was able to determine four days after treatment that experimental therapies for sarcoma were fighting the cancer in xenograft models

The mTOR inhibitor temsirolimus has limited utility in combination with frontline bevacizumab and as a second-line single agent for patients with metastatic renal cell carcinoma

The first oncology-specific accountable care organization (ACO) reported more than a 2% savings in its first year of existence.

The FDA has approved revised US Prescribing Information (USPI) and a Risk Evaluation and Mitigation Strategy (REMS) for Iclusig® (ponatinib).

Alterations in specific genes involved in the formation of tissues and organs during embryonic development could be responsible for survival disparities seen between African-American and non-Latino white men with head and neck cancer.

The tiny "raise" touted in the latest temporary fix to Medicare's Sustainable Growth Rate, which was wrapped inside the bipartisan budget deal headed to President Obama's desk, is anything but good news for oncologists.

Aldoxorubicin demonstrated significant benefit to progression-free survival (PFS) compared with doxorubicin in patients with first-line, metastatic, locally advanced or unresectable soft tissue sarcomas

Hyponatremia is significantly associated with worse outcomes in patients with metastatic renal cell carcinoma (mRCC) who received treatment with VEGF- and mTOR-targeted agents